ANTEOTECH LTD — AGM Information 2011

Oct 23, 2011

==> picture [290 x 147] intentionally omitted <==

Anteo Diagnostics (ASX:ADO) FY2011 Annual General Meeting (AGM)

Better Binding - Faster Dr. Geoff Cumming - CEO Monday 24 October, 2011

CEO’s Address – Dr Geoff Cumming

• A year of significant progress for Anteo

• An experienced and capable Board of Directors now in place

  • Appointments of Ms Sandra Anderson & Mr Mark Bouris

• Highly experienced management and technical team – Dr Joe Maeji, Dr Nevin Abernethy, Dr Tina Baumgartner

• Anteo is financially strong – cash on hand (As at 30 June 2011) $6.85m – Well funded to the end of calendar year 2013, excluding any future revenues

• The platform is now in place to realise the value of the Mix&Go™ technology

• We are grateful for the continued support from our shareholders

==> picture [153 x 78] intentionally omitted <==

CEO’s Address - Dr Geoff Cumming

FY2011 Highlights

• July 2010 – ADO announces agreed terms with Merck Chimie SAS

• February 2011 – ADO raises $5.1m from existing shareholders through option conversion

• February 2011 – Bangs Laboratories launches second product using Mix&Go™

• March 2011 – European Patent Office confirms intention to grant the ‘Generation of Surface Coating Diversity’ patent for Mix&Go™

==> picture [221 x 112] intentionally omitted <==

CEO’s Address - Dr. Geoff Cumming

A snapshot of the Mix&Go™ Technology

• ADO has developed Mix&Go™ – a molecular ‘glue’ that significantly improves pathology tests

• Mix&Go™ is a novel ‘glue’ - like a two sided velcro

• Mix&Go™ technology results in earlier detection of disease (more treatment options) OR less expensive test manufacture (less antibody used)

• Mix&Go™ is proven and already licensed to two major healthcare companies – Bangs Laboratories and Merck

• Potential to access numerous and large healthcare segments – pathology (IVD), research, point of care diagnostics, immunoprecipitation

• Mix&Go™ has a solid pipeline of opportunity – over 60 global healthcare companies are currently assessing Mix&Go™ in-house for use/licensing

==> picture [153 x 78] intentionally omitted <==

CEO’s Address - Dr Geoff Cumming

Anteo’s Short Term Value Drivers In Vitro Diagnostics (IVD) Market

• Global leading IVD companies currently undertaking real time stability testing and associated studies for Mix&Go™

• The IVD market is valued at $10 billion per annum

Research & Development (R&D)

• Currently 2-3 healthcare R&D companies actively considering Mix&Go™

• Short term revenue opportunities as R&D companies take less time on approval processes

• ADO pushing into new areas of research, including the effective use of microtitre plates

• ADO currently researching our ability to improve the efficacy of multiplexing - multiple tests from a single bead

==> picture [175 x 89] intentionally omitted <==

A strong start to FY2012

• Appointment of highly experienced Non-Executive Chairman

• Recently hired three new Scientists

• Continued growth of pipeline of opportunities

• Anteo is in excellent shape and well positioned for the year ahead

==> picture [185 x 94] intentionally omitted <==

Shareholder Questions

Dr. Geoff Cumming Chief Executive Officer Anteo Diagnostics Limited Tel: +61 2 8823 3110

==> picture [175 x 89] intentionally omitted <==